The time it takes for the therapeutic effects of Sotoracib (AMG510) to appear varies from person to person.

Soteracib (AMG510) is an innovative targeted therapy drug, and the time it takes for its efficacy to appear is a matter of great concern. However, due to the individual differences and disease status of each patient, the onset of action of sotoraxib is not fixed and has a certain range of variation.

After a patient starts taking sotoraxib, the drug quickly enters the body and interacts with the KRAS G12C mutant protein, thereby inhibiting its activity. However, because tumor cells have unique growth and metabolic properties, different patients respond to drugs at different rates. Therefore, the time when the therapeutic effect of sotorasibu appears varies from person to person and cannot be generalized.

Clinical studies have shown that sotoraxib has certain efficacy in the treatment of non-small cell lung cancer. In a study involving 124 patients, 45 (36%) had their tumors disappear or shrink by at least 30% with sotoraxib, and the median duration of response was 10 months. Another study showed that compared with the chemotherapy drug docetaxel, patients in the sotoraxib group had a higher 12-month progression-free survival rate, 24.8% and 10.1% respectively.

In some cases, patients may observe significant effects, such as tumor shrinkage, improvement in symptoms, and decreases in related tumor markers, within weeks of starting treatment. However, in other patients, it may take longer to see the effects of treatment. This depends on a variety of factors, including the patient's overall health, the severity of the disease, and the sensitivity of the tumor cells to the drug. It is important to note that sotorasiib is often used as a long-term treatment to maintain its therapeutic effects.